A Phase 3 interventional study of YF-17D and TDV in Dengue, sponsored by Takeda. Completed at 11 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.
Among the 17 studies in Dengue by Takeda, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 6th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:
Takeda · Sites in Colombia, Thailand
Ages 6 mo–20 mo · Healthy volunteers
Takeda · Sites in Indonesia, Malaysia, Thailand
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2018.
This study's enrollment of 900 is above the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 400 across the 15 interventional studies, 36,000 across the 2 observational. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
2 of the studies in Dengue by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579755Phase 3TakedaA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | 2027-04-14 |
| NCT06388785TakedaA Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia | 2027-05-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Dengue by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60 years living in country non-endemic for both dengue and YF.
The vaccine tested in this study is TDV also known as TAK-003 (DENVax). TDV with concomitant and sequential administration of yellow fever (YF-17D) vaccine will be tested to assess immunogenicity and safety in healthy adult participants in non-endemic area(s) for both dengue and YF.
The study will enroll 900 healthy participants. Participants will be randomized to 3 groups in 1:1:1 ratio and will be administered concomitantly and sequentially. The 3 groups are:
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 360 days. Participants will make multiple visits to the clinic with a 6-month follow up including a final visit at Day 360 for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
Biological: YF-17D · Biological: TDV · Drug: Placebo
TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
Biological: YF-17D · Biological: TDV · Drug: Placebo
TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
Biological: YF-17D · Biological: TDV · Drug: Placebo
YF-17D SC injection.
TDV SC injection.
Also known as: TAK-003, DENVax
Normal Saline (0.9% NaCl) SC injection.
Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)
Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10. Immunological naivety to YF and DENV was defined as Baseline reciprocal neutralizing antibody titers \<10 for YF and for the 4 dengue serotypes. The 95% CI was calculated using exact Clopper-Pearson method.
Time frame: Day 30
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
GMTs of neutralizing antibodies was measured by microneutralization test 50% \[MNT50\] for each of the 4 dengue serotypes. The 4 DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1 month post -first, second, and third vaccination (Days 30, 120, and 210, respectively)
Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
Seropositivity rate was defined as the percentage of seropositive participants as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for each dengue serotype were analyzed and was summarized as: DENV-1, DENV-2, DENV-3, and DENV-4.
Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, -second, and -third vaccination (Days 30, 120, and 210, respectively)
Percentage of Participants Who Are Seropositive for Multiple (2, 3 or 4) Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
Seropositivity rate was defined as the percentage of seropositive participants, as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for multiple dengue serotypes were summarized in the following categories: at least bivalent, at least trivalent and tetravalent.
Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, second, and -third vaccination (Days 30, 120, and 210, respectively)
Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT
Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10.
Time frame: 1-month post third vaccination (Day 210)
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline
Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.
Time frame: 1-month post-first vaccination (Day 30)
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline
Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.
Time frame: 1-month post-third vaccination (Day 210)
Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Following Each Vaccination Dose by Severity
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Solicited local injection site AEs recorded from participant's-diary. Severity grade at injection site for pain: Grade 0 (No Pain), 1 (did not interfere with daily activity), 2 (interference with daily activity with or without treatment) and 3 (prevents daily activity with or without treatment). For erythema: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). For swelling: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). Percentages were rounded off for each category. For the first vaccination (Vac.) YF is given in Arm 1 (A1) and TDV is given in Arm 2 (A2). A1 = YF for Group 1, Placebo for Group 2, and YF for Group 3; A2 = Placebo for Group 1, TDV for Group 2, and TDV for Group 3.
Time frame: Within 7 Days of each Vaccination (day of vaccination + 6 days)
Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination Dose by Severity
Solicited systemic AEs (fever, headache, asthenia, malaise, and myalgia) recorded from participant's-diary. Severity grades for headache are grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents normal activity with or without treatment). Severity grades for asthenia, malaise and myalgia is grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity), 3 (severe: prevents daily activity). Fever is defined as greater than or equal to 38º C or 100.4º C. Fever was excluded from the overall count as no severity grading was applied for it. Percentages were rounded off for each category.
Time frame: Within 14 Days of each Vaccination (day of vaccination + 13 days)
Percentage of Participants With Any Unsolicited Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
Time frame: Within 28 days (day of vaccination + 27 days) after each vaccination
Percentage of Participants With Medically Attended Adverse Events (MAAEs)
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: From first vaccination (Day 1) through end of study (Day 360)
Percentage of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.
Time frame: From first vaccination (Day 1) through end of study (Day 360)
Participants took part in the study at 11 investigative sites in the United States from 28 Feb 2018 to 22 May 2019.
| Milestone | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Started | 300 | 300 | 300 |
| Completed | 246 | 247 | 246 |
| Not completed | 54 | 53 | 54 |
| Withdrew: Adverse event | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 44 | 40 | 42 |
| Withdrew: Withdrawal of consent | 5 | 9 | 11 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Reason not specified | 2 | 2 | 0 |
Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10. Immunological naivety to YF and DENV was defined as Baseline reciprocal neutralizing antibody titers \<10 for YF and for the 4 dengue serotypes. The 95% CI was calculated using exact Clopper-Pearson method.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT) | 99.5 (97.4 to 100.0) | 9.8 (6.3 to 14.4) | 99.1 (96.9 to 99.9) |
GMTs of neutralizing antibodies was measured by microneutralization test 50% \[MNT50\] for each of the 4 dengue serotypes. The 4 DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.
| titer | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Day 30, DENV-1 | 6.0 (5.4 to 6.7) | 226.2 (178.7 to 286.4) | 119.4 (93.0 to 153.4) |
| Day 30, DENV-2 | 7.7 (6.6 to 9.0) | 5431.1 (3930.2 to 7505.3) | 650.8 (438.1 to 966.7) |
| Day 30, DENV-3 | 5.8 (5.2 to 6.4) | 172.0 (129.4 to 228.5) | 70.9 (54.1 to 92.9) |
| Day 30, DENV-4 | 6.1 (5.4 to 6.9) | 142.0 (108.7 to 185.4) | 49.8 (39.3 to 63.1) |
| Day 90, DENV-1 | 6.0 (5.5 to 6.6) | 147.5 (114.6 to 189.7) | 95.1 (74.0 to 122.2) |
| Day 90, DENV-2 | 7.8 (6.6 to 9.2) | 2846.5 (2273.6 to 3563.7) | 1547.2 (1198.1 to 1998.0) |
| Day 90, DENV-3 | 5.9 (5.3 to 6.5) | 73.1 (58.3 to 91.7) | 70.1 (57.3 to 85.7) |
| Day 90, DENV-4 | 5.9 (5.3 to 6.4) | 56.1 (45.0 to 70.0) | 49.1 (41.0 to 58.8) |
| Day 120, DENV-1 | 403.9 (335.3 to 486.6) | 297.1 (239.8 to 368.1) | 182.6 (145.5 to 229.2) |
| Day 120, DENV-2 | 4691.3 (3688.6 to 5966.4) | 2616.1 (2133.1 to 3208.4) | 1947.7 (1639.9 to 2313.2) |
| Day 120, DENV-3 | 636.4 (525.6 to 770.5) | 131.4 (110.5 to 156.3) | 104.5 (87.9 to 124.1) |
| Day 120, DENV-4 | 678.5 (568.7 to 809.4) | 111.8 (94.5 to 132.1) | 97.7 (81.4 to 117.3) |
| Day 180, DENV-1 | 251.4 (209.0 to 302.3) | 227.0 (177.4 to 290.4) | 147.0 (115.8 to 186.6) |
| Day 180, DENV-2 | 2413.5 (2038.6 to 2857.3) | 1959.3 (1584.1 to 2423.5) | 1800.0 (1535.8 to 2109.7) |
| Day 180, DENV-3 | 342.3 (294.6 to 397.9) | 84.9 (70.1 to 102.8) | 75.8 (65.2 to 88.3) |
| Day 180, DENV-4 | 358.4 (302.8 to 424.2) | 83.7 (69.9 to 100.3) | 69.6 (59.0 to 82.3) |
| Day 210, DENV-1 | 267.5 (221.5 to 323.2) | 679.9 (549.7 to 841.0) | 138.2 (108.3 to 176.2) |
| Day 210, DENV-2 | 2248.0 (1902.3 to 2656.6) | 3798.1 (3139.4 to 4595.0) | 1688.0 (1431.7 to 1990.1) |
| Day 210, DENV-3 | 301.8 (262.7 to 346.6) | 406.4 (345.4 to 478.1) | 64.3 (54.3 to 76.2) |
| Day 210, DENV-4 | 347.4 (297.5 to 405.6) | 436.5 (374.7 to 508.5) | 56.6 (46.9 to 68.2) |
Seropositivity rate was defined as the percentage of seropositive participants as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for each dengue serotype were analyzed and was summarized as: DENV-1, DENV-2, DENV-3, and DENV-4.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Day 30, DENV-1 | 6.5 (3.4 to 11.1) | 93.3 (88.8 to 96.4) | 87.6 (81.9 to 92.0) |
| Day 30, DENV-2 | 15.8 (10.8 to 21.8) | 95.9 (92.0 to 98.2) | 88.1 (82.6 to 92.4) |
| Day 30, DENV-3 | 4.3 (1.9 to 8.4) | 88.1 (82.7 to 92.3) | 80.5 (74.1 to 86.0) |
| Day 30, DENV-4 | 7.1 (3.8 to 11.8) | 89.6 (84.4 to 93.6) | 78.4 (71.7 to 84.1) |
| Day 90, DENV-1 | 8.3 (4.8 to 13.2) | 90.4 (85.5 to 94.0) | 89.4 (84.1 to 93.4) |
| Day 90, DENV-2 | 14.6 (9.9 to 20.4) | 97.1 (93.8 to 98.9) | 94.2 (89.8 to 97.1) |
| Day 90, DENV-3 | 5.7 (2.9 to 10.0) | 84.6 (79.0 to 89.2) | 90.5 (85.4 to 94.3) |
| Day 90, DENV-4 | 6.3 (3.3 to 10.7) | 84.6 (79.0 to 89.2) | 89.4 (84.1 to 93.4) |
| Day 120, DENV-1 | 99.4 (96.9 to 100.0) | 99.5 (97.2 to 100.0) | 99.4 (96.9 to 100.0) |
| Day 120, DENV-2 | 99.4 (96.9 to 100.0) | 98.5 (95.6 to 99.7) | 99.4 (96.9 to 100.0) |
| Day 120, DENV-3 | 98.9 (95.9 to 99.9) | 98.5 (95.6 to 99.7) | 98.3 (95.1 to 99.6) |
| Day 120, DENV-4 | 99.4 (96.9 to 100.0) | 99.0 (96.4 to 99.9) | 97.7 (94.3 to 99.4) |
| Day 180, DENV-1 | 99.0 (96.3 to 99.9) | 97.1 (93.8 to 98.9) | 95.8 (91.8 to 98.2) |
| Day 180, DENV-2 | 100.0 (98.1 to 100.0) | 97.6 (94.5 to 99.2) | 99.5 (97.1 to 100.0) |
| Day 180, DENV-3 | 99.5 (97.1 to 100.0) | 92.8 (88.4 to 95.9) | 96.3 (92.5 to 98.5) |
| Day 180, DENV-4 | 99.0 (96.3 to 99.9) | 96.6 (93.2 to 98.6) | 96.8 (93.2 to 98.8) |
| Day 210, DENV-1 | 100.0 (97.9 to 100.0) | 99.5 (97.1 to 100.0) | 96.6 (92.7 to 98.7) |
| Day 210, DENV-2 | 100.0 (97.9 to 100.0) | 99.5 (97.1 to 100.0) | 99.4 (96.9 to 100.0) |
| Day 210, DENV-3 | 100.0 (97.9 to 100.0) | 99.5 (97.1 to 100.0) | 93.2 (88.4 to 96.4) |
| Day 210, DENV-4 | 99.4 (96.8 to 100.0) | 99.5 (97.1 to 100.0) | 94.3 (89.8 to 97.2) |
Seropositivity rate was defined as the percentage of seropositive participants, as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for multiple dengue serotypes were summarized in the following categories: at least bivalent, at least trivalent and tetravalent.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Day 30, At Least Bivalent | 5.4 (2.6 to 9.8) | 96.9 (93.4 to 98.9) | 90.8 (85.7 to 94.6) |
| Day 30, At Least Trivalent | 4.9 (2.3 to 9.1) | 91.7 (86.9 to 95.2) | 81.6 (75.3 to 86.9) |
| Day 30, Tetravalent | 3.8 (1.5 to 7.7) | 79.3 (72.9 to 84.8) | 65.9 (58.6 to 72.7) |
| Day 90, At Least Bivalent | 6.3 (3.3 to 10.7) | 95.7 (91.9 to 98.0) | 94.7 (90.5 to 97.4) |
| Day 90, At Least Trivalent | 5.7 (2.9 to 10.0) | 87.0 (81.7 to 91.3) | 88.9 (83.5 to 93.0) |
| Day 90, Tetravalent | 5.7 (2.9 to 10.0) | 75.5 (69.1 to 81.2) | 82.0 (75.8 to 87.2) |
| Day 120, At Least Bivalent | 99.4 (96.9 to 100.0) | 99.5 (97.2 to 100.0) | 99.4 (96.9 to 100.0) |
| Day 120, At Least Trivalent | 99.4 (96.9 to 100.0) | 99.5 (97.2 to 100.0) | 98.3 (95.1 to 99.6) |
| Day 120, Tetravalent | 98.9 (95.9 to 99.9) | 97.0 (93.5 to 98.9) | 97.7 (94.3 to 99.4) |
| Day 180, At Least Bivalent | 99.5 (97.1 to 100.0) | 99.0 (96.6 to 99.9) | 98.9 (96.2 to 99.9) |
| Day 180, At Least Trivalent | 99.0 (96.3 to 99.9) | 97.6 (94.5 to 99.2) | 98.4 (95.4 to 99.7) |
| Day 180, Tetravalent | 99.0 (96.3 to 99.9) | 88.0 (82.8 to 92.1) | 91.5 (86.6 to 95.1) |
| Day 210, At Least Bivalent | 100.0 (97.9 to 100.0) | 99.5 (97.1 to 100.0) | 98.9 (96.0 to 99.9) |
| Day 210, At Least Trivalent | 100.0 (97.9 to 100.0) | 99.5 (97.1 to 100.0) | 96.0 (92.0 to 98.4) |
| Day 210, Tetravalent | 99.4 (96.8 to 100.0) | 99.5 (97.1 to 100.0) | 89.2 (83.7 to 93.4) |
Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT | 100.0 (97.9 to 100.0) | 98.4 (95.4 to 99.7) | 98.9 (96.0 to 99.9) |
Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.
| titer | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline | 4245.7 (3526.5 to 5111.6) | 6.0 (5.5 to 6.6) | 4321.7 (3652.5 to 5113.6) |
Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.
| titer | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline | 2341.6 (1938.2 to 2829.0) | 3078.2 (2452.0 to 3864.4) | 1089.1 (888.1 to 1335.7) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Solicited local injection site AEs recorded from participant's-diary. Severity grade at injection site for pain: Grade 0 (No Pain), 1 (did not interfere with daily activity), 2 (interference with daily activity with or without treatment) and 3 (prevents daily activity with or without treatment). For erythema: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). For swelling: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). Percentages were rounded off for each category. For the first vaccination (Vac.) YF is given in Arm 1 (A1) and TDV is given in Arm 2 (A2). A1 = YF for Group 1, Placebo for Group 2, and YF for Group 3; A2 = Placebo for Group 1, TDV for Group 2, and TDV for Group 3.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| After Vac. 1, Any Local AEs, A1 | 13.1 | 16.8 | 27.3 |
| After Vac. 1, Any Local AEs, A2 | 13.1 | 44.2 | 48.9 |
| After Vac. 1, Pain: Any Severity, A1 | 12.1 | 16.5 | 24.1 |
| After Vac. 1, Pain: Any Severity, A2 | 12.8 | 40.0 | 42.2 |
| After Vac. 1, Pain: Mild, A1 | 9.0 | 13.7 | 21.3 |
| After Vac. 1, Pain: Mild, A2 | 10.0 | 35.1 | 34.0 |
| After Vac. 1, Pain: Moderate, A1 | 3.1 | 2.5 | 2.1 |
| After Vac. 1, Pain: Moderate, A2 | 2.4 | 4.6 | 6.7 |
| After Vac. 1, Pain: Severe, A1 | 0 | 0.4 | 0.7 |
| After Vac. 1, Pain: Severe, A2 | 0.3 | 0.4 | 1.4 |
| After Vac. 1, Erythema: Any Severity, A1 | 2.4 | 1.8 | 3.9 |
| After Vac. 1, Erythema: Any Severity, A2 | 0.7 | 19.6 | 19.5 |
| After Vac. 1,Erythema:Mild:2.5-5(cm), A1 | 1.7 | 1.8 | 3.9 |
| After Vac. 1,Erythema:Mild:2.5-5(cm), A2 | 0 | 17.5 | 18.8 |
| After Vac. 1,Erythema:Moderate:>5-<=10(cm), A1 | 0.3 | 0 | 0 |
| After Vac. 1,Erythema:Moderate:>5-<=10(cm), A2 | 0.7 | 1.8 | 0.4 |
| After Vac. 1,Erythema:Severe:>10(cm), A1 | 0.3 | 0 | 0 |
| After Vac. 1,Erythema:Severe:>10(cm), A2 | 0 | 0 | 0.4 |
| After Vac. 1, Erythema: Missing Severity, A2 | 0 | 0.4 | 0 |
| After Vac. 1, Swelling: Any Severity, A1 | 0.7 | 1.1 | 2.1 |
| After Vac. 1, Swelling: Any Severity, A2 | 0.3 | 4.2 | 5.3 |
| After Vac. 1,Swelling:Mild:2.5-5(cm), A1 | 0.3 | 1.1 | 1.8 |
| After Vac. 1,Swelling:Mild:2.5-5(cm), A2 | 0 | 4.2 | 4.6 |
| After Vac. 1,Swelling:Moderate:>5-<=10(cm), A1 | 0 | 0 | 0.4 |
| After Vac. 1,Swelling:Moderate:>5-<=10(cm), A2 | 0.3 | 0 | 0.4 |
| After Vac. 1,Swelling:Severe:>10(cm), A1 | 0.3 | 0 | 0 |
| After Vac. 1,Swelling:Severe:>10(cm), A2 | 0 | 0 | 0.4 |
| After Vac. 2, Any Local AEs | 31.1 | 35.9 | 35.7 |
| After Vac. 2, Pain: Any Severity | 27.8 | 30.1 | 31.7 |
| After Vac. 2, Pain: Mild | 23.6 | 25.8 | 27.8 |
| After Vac. 2, Pain: Moderate | 3.4 | 3.5 | 2.8 |
| After Vac. 2, Pain: Severe | 0.8 | 0.8 | 1.2 |
| After Vac. 2, Erythema: Any Severity | 12.3 | 14.5 | 13.1 |
| After Vac. 2,Erythema:Mild:2.5-5(cm) | 10.7 | 10.5 | 10.7 |
| After Vac. 2,Erythema:Moderate:>5-<=10(cm) | 1.1 | 3.1 | 2.4 |
| After Vac. 2,Erythema:Severe:>10(cm) | 0.4 | 0 | 0 |
| After Vac. 2, Erythema: Missing Severity | 0 | 0.8 | 0 |
| After Vac. 2, Swelling: Any Severity | 2.7 | 5.9 | 5.6 |
| After Vac. 2,Swelling:Mild:2.5-5(cm) | 2.3 | 4.3 | 4.8 |
| After Vac. 2,Swelling:Moderate:>5-<=10(cm) | 0.4 | 1.6 | 0.8 |
| After Vac. 3, Any Local AEs | 27.8 | 10.4 | 10.6 |
| After Vac. 3, Pain: Any Severity | 24.9 | 10.4 | 9.7 |
| After Vac. 3, Pain: Mild | 20.3 | 9.1 | 7.9 |
| After Vac. 3, Pain: Moderate | 4.2 | 0.9 | 0.9 |
| After Vac. 3, Pain: Severe | 0.4 | 0.4 | 0.9 |
| After Vac. 3, Erythema: Any Severity | 9.7 | 0.4 | 0.9 |
| After Vac. 3,Erythema:Mild:2.5-5(cm) | 8.5 | 0 | 0.4 |
| After Vac. 3,Erythema:Moderate:>5-<=10(cm) | 0.4 | 0.4 | 0 |
| After Vac. 3,Erythema:Severe:>10(cm) | 0 | 0 | 0.4 |
| After Vac. 3, Erythema: Missing Severity | 0.8 | 0 | 0 |
| After Vac. 3, Swelling: Any Severity | 4.2 | 0 | 0 |
| After Vac. 3,Swelling:Mild:2.5-5(cm) | 3.4 | 0 | 0 |
| After Vac. 3, Swelling: Missing Severity | 0.8 | 0 | 0 |
Solicited systemic AEs (fever, headache, asthenia, malaise, and myalgia) recorded from participant's-diary. Severity grades for headache are grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents normal activity with or without treatment). Severity grades for asthenia, malaise and myalgia is grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity), 3 (severe: prevents daily activity). Fever is defined as greater than or equal to 38º C or 100.4º C. Fever was excluded from the overall count as no severity grading was applied for it. Percentages were rounded off for each category.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| After Vaccination 1, Any Systemic AEs | 43.6 | 49.8 | 51.8 |
| After Vaccination 1, Headache: Any Severity | 31.8 | 33.0 | 39.9 |
| After Vaccination 1, Headache: Mild | 21.5 | 22.5 | 26.0 |
| After Vaccination 1, Headache: Moderate | 8.7 | 8.4 | 9.3 |
| After Vaccination 1, Headache: Severe | 1.7 | 2.1 | 4.6 |
| After Vaccination 1, Asthenia: Any Severity | 17.6 | 21.1 | 20.3 |
| After Vaccination 1, Asthenia: Mild | 10.0 | 11.2 | 13.9 |
| After Vaccination 1, Asthenia: Moderate | 5.5 | 7.7 | 4.6 |
| After Vaccination 1, Asthenia: Severe | 2.1 | 2.1 | 1.8 |
| After Vaccination 1, Malaise: Any Severity | 20.8 | 20.7 | 24.5 |
| After Vaccination 1, Malaise: Mild | 12.8 | 11.6 | 13.8 |
| After Vaccination 1, Malaise: Moderate | 6.2 | 4.6 | 8.5 |
| After Vaccination 1, Malaise: Severe | 1.7 | 4.6 | 2.1 |
| After Vaccination 1, Myalgia: Any Severity | 23.2 | 29.5 | 29.4 |
| After Vaccination 1, Myalgia: Mild | 15.6 | 19.6 | 19.1 |
| After Vaccination 1, Myalgia: Moderate | 5.5 | 7.0 | 8.5 |
| After Vaccination 1, Myalgia: Severe | 2.1 | 2.8 | 1.8 |
| After Vaccination 1, Fever: Any Severity | 1.4 | 6.0 | 1.1 |
| After Vaccination 1,Fever:38.0-<38.5 | 0.3 | 3.6 | 0.4 |
| After Vaccination 1,Fever:38.5-<39.0 | 0.3 | 1.8 | 0.7 |
| After Vaccination 1,Fever:39.0-<39.5 | 0.3 | 0.4 | 0 |
| After Vaccination 1,Fever:39.5-<40.0 | 0 | 0.4 | 0 |
| After Vaccination 1,Fever:≥41.0 | 0.3 | 0 | 0 |
| After Vaccination 2, Any Systemic AEs | 33.3 | 29.3 | 31.7 |
| After Vaccination 2, Headache: Any Severity | 22.7 | 15.6 | 21.0 |
| After Vaccination 2, Headache: Mild | 13.3 | 10.2 | 11.9 |
| After Vaccination 2, Headache: Moderate | 6.4 | 4.3 | 7.1 |
| After Vaccination 2, Headache: Severe | 3.0 | 1.2 | 2.0 |
| After Vaccination 2, Asthenia: Any Severity | 13.3 | 8.6 | 11.5 |
| After Vaccination 2, Asthenia: Mild | 8.3 | 2.7 | 6.7 |
| After Vaccination 2, Asthenia: Moderate | 3.8 | 4.3 | 2.4 |
| After Vaccination 2, Asthenia: Severe | 1.1 | 1.6 | 2.4 |
| After Vaccination 2, Malaise: Any Severity | 14.0 | 9.8 | 9.9 |
| After Vaccination 2, Malaise: Mild | 7.6 | 4.3 | 4.4 |
| After Vaccination 2, Malaise: Moderate | 4.5 | 4.3 | 4.0 |
| After Vaccination 2, Malaise: Severe | 1.9 | 1.2 | 1.6 |
| After Vaccination 2, Myalgia: Any Severity | 20.8 | 18.8 | 20.2 |
| After Vaccination 2, Myalgia: Mild | 14.4 | 13.3 | 12.3 |
| After Vaccination 2, Myalgia: Moderate | 5.3 | 4.3 | 5.2 |
| After Vaccination 2, Myalgia: Severe | 1.1 | 1.2 | 2.8 |
| After Vaccination 2, Fever: Any Severity | 3.1 | 1.2 | 1.2 |
| After Vaccination 2,Fever:38.0-<38.5 | 1.5 | 0.4 | 0.4 |
| After Vaccination 2,Fever:38.5-<39.0 | 1.2 | 0.8 | 0.4 |
| After Vaccination 2,Fever:39.0-<39.5 | 0.4 | 0 | 0 |
| After Vaccination 2,Fever:39.5-<40.0 | 0 | 0 | 0.4 |
| After Vaccination 3, Any Systemic AEs | 24.4 | 27.4 | 22.8 |
| After Vaccination 3, Headache: Any Severity | 17.2 | 17.4 | 20.2 |
| After Vaccination 3, Headache: Mild | 10.1 | 11.3 | 13.6 |
| After Vaccination 3, Headache: Moderate | 6.3 | 4.8 | 4.8 |
| After Vaccination 3, Headache: Severe | 0.8 | 1.3 | 1.8 |
| After Vaccination 3, Asthenia: Any Severity | 10.5 | 9.1 | 7.0 |
| After Vaccination 3, Asthenia: Mild | 6.3 | 7.4 | 3.9 |
| After Vaccination 3, Asthenia: Moderate | 3.8 | 1.7 | 2.6 |
| After Vaccination 3, Asthenia: Severe | 0.4 | 0 | 0.4 |
| After Vaccination 3, Malaise: Any Severity | 11.3 | 13.5 | 11.4 |
| After Vaccination 3, Malaise: Mild | 6.3 | 9.1 | 7.9 |
| After Vaccination 3, Malaise: Moderate | 3.8 | 3.5 | 2.6 |
| After Vaccination 3, Malaise: Severe | 1.3 | 0.9 | 0.9 |
| After Vaccination 3, Myalgia: Any Severity | 12.6 | 12.2 | 7.9 |
| After Vaccination 3, Myalgia: Mild | 7.6 | 7.8 | 4.8 |
| After Vaccination 3, Myalgia: Moderate | 3.8 | 3.9 | 2.6 |
| After Vaccination 3, Myalgia: Severe | 1.3 | 0.4 | 0.4 |
| After Vaccination 3, Fever: Any Severity | 1.3 | 0 | 1.3 |
| After Vaccination 3,Fever:38.0-<38.5 | 0.9 | 0 | 0.9 |
| After Vaccination 3,Fever:38.5-<39.0 | 0.4 | 0 | 0 |
| After Vaccination 3,Fever:39.0-<39.5 | 0 | 0 | 0.4 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| After First Vaccination | 11.7 | 17.3 | 14.0 |
| After Second Vaccination | 8.8 | 10.4 | 9.1 |
| After Third Vaccination | 4.4 | 5.4 | 4.7 |
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Percentage of Participants With Medically Attended Adverse Events (MAAEs) | 14.3 | 15.3 | 15.3 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.
| percentage of participants | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 4.3 | 3.3 | 2.3 |
Collected over All-Cause Mortality and Serious Adverse Events: From first vaccination (Day 1) through end of study (Day 360); Other Adverse Events: From any vaccination (Day 1, Day 90, and Day 180) up to 28 days post vaccination.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: YF-17D + Placebo/TDV/TDV | 0/300 (0%) | 13/300 (4.3%) | 11/300 (3.7%) |
| Group 2: TDV + Placebo/TDV/YF-17D | 1/300 (0.3%) | 10/300 (3.3%) | 23/300 (7.7%) |
| Group 3: TDV + YF-17D/TDV/Placebo | 1/300 (0.3%) | 7/300 (2.3%) | 19/300 (6.3%) |
| Event | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/300 | 1/300 | 2/300 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/300 | 0/300 | 0/300 |
| Cardiac arrestCardiac disorders | 0/300 | 1/300 | 0/300 |
| HypothyroidismEndocrine disorders | 0/300 | 0/300 | 1/300 |
| Abdominal painGastrointestinal disorders | 0/300 | 1/300 | 0/300 |
| Alcoholic pancreatitisGastrointestinal disorders | 0/300 | 1/300 | 0/300 |
| Inguinal herniaGastrointestinal disorders | 1/300 | 0/300 | 0/300 |
| Large intestinal obstructionGastrointestinal disorders | 0/300 | 1/300 | 0/300 |
| MegacolonGastrointestinal disorders | 0/300 | 1/300 | 0/300 |
| Peptic ulcerGastrointestinal disorders | 1/300 | 0/300 | 0/300 |
| Event | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/300 | 13/300 | 4/300 |
| Injection site bruisingGeneral disorders | 4/300 | 5/300 | 10/300 |
| Injection site pruritusGeneral disorders | 3/300 | 7/300 | 8/300 |
Safety Set included all randomized participants who received at least 1 dose of the trial vaccines.
| Age, Continuous(years) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 12.41 | 40.0 ± 12.91 | 41.4 ± 12.67 | 41.0 ± 12.67 |
| Sex: Female, Male(Participants) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Female | 167 | 170 | 176 | 513 |
| Male | 133 | 130 | 124 | 387 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 26 | 25 | 31 | 82 |
| Not Hispanic or Latino | 272 | 270 | 266 | 808 |
| Unknown or Not Reported | 2 | 5 | 3 | 10 |
| Race (NIH/OMB)(Participants) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 2 | 7 |
| Asian | 3 | 4 | 7 | 14 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 1 | 3 |
| Black or African American | 77 | 103 | 84 | 264 |
| White | 205 | 186 | 201 | 592 |
| More than one race | 5 | 0 | 2 | 7 |
| Unknown or Not Reported | 5 | 5 | 3 | 13 |
| Height(cm) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Mean | 171.3 ± 9.29 | 170.1 ± 9.05 | 170.5 ± 8.85 | 170.6 ± 9.07 |
| Weight(kg) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Mean | 82.40 ± 15.40 | 78.52 ± 14.65 | 80.87 ± 16.94 | 80.60 ± 15.75 |
| Body Mass Index (BMI)(kg/m^2) | Group 1: YF-17D + Placebo/TDV/TDV | Group 2: TDV + Placebo/TDV/YF-17D | Group 3: TDV + YF-17D/TDV/Placebo | Total |
|---|---|---|---|---|
| Mean | 28.00 ± 4.29 | 27.07 ± 4.30 | 27.66 ± 4.49 | 27.58 ± 4.37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Feb 2018 to primary completion in May 2018, 2 months.
Results were first posted in Oct 2020, 2 years 4 months after primary completion. A results delay was requested in May 2019.
Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.